Inventor · disambiguated record
Nadthakarn Boland
Also filed as: BOLAND NADTHAKARN
9 granted patents·7 pending applications·12 citations·filing 2017–2025
83Inventor score
Files withUNIV TEXAS7INNOVENT BIOLOGICS SUZHOU CO LTD2SURFACE ONCOLOGY INC2SURFACE ONCOLOGY LLC2INNOVENT CELLS PHARMACEUTICALS SUZHOU CO LTD1
Top patents by PatentIndex Score
16 records- 0188US11976128B2Human PD-L2 antibodies and methods of use thereforUNIV TEXAS·Filed 2019·Granted May 7, 2024·2 cites·21 claims
- 0288US11525002B2Human PD-L1 antibodies and methods of use thereforUNIV TEXAS·Filed 2018·Granted Dec 13, 2022·3 cites·20 claims
- 0386US12428489B2Human PD-L2 antibodies and methods of use thereforUNIV TEXAS·Filed 2024·Granted Sep 30, 2025·0 cites·10 claims
- 0486US11214619B2Anti-CD112R compositions and methodsSURFACE ONCOLOGY INC·Filed 2019·Granted Jan 4, 2022·4 cites·19 claims
- 0584US12162941B2Anti-CD112R compositions and methodsSURFACE ONCOLOGY LLC·Filed 2021·Granted Dec 10, 2024·1 cites·19 claims
- 0682US12325747B2Human PD-L1 antibodies and methods of use thereforUNIV TEXAS·Filed 2022·Granted Jun 10, 2025·0 cites·11 claims
- 0781US2025059282A1Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use thereforUNIV TEXAS·Filed 2024·Application pending·0 cites
- 0880US2025320296A1Human pd-l1 antibodies and methods of use thereforUNIV TEXAS·Filed 2025·Application pending·0 cites
- 0979US2025051449A1Anti-CD112R Compositions and MethodsSURFACE ONCOLOGY LLC·Filed 2024·Application pending·0 cites
- 1076US11279758B2Anti-CD112R compositions and methodsSURFACE ONCOLOGY INC·Filed 2019·Granted Mar 22, 2022·1 cites·22 claims
- 1175US11485795B2Anti-PCSK9 antibody and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2017·Granted Nov 1, 2022·1 cites·29 claims
- 1265US12134648B2Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use thereforUNIV TEXAS·Filed 2019·Granted Nov 5, 2024·0 cites·16 claims
- 1359US2025034268A1Antibody binding to bcma and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 1458US2025270323A1Hhla2 binding agents with novel activityNEXTPOINT THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1558US2025041416A1P329g antibody targeting bcma, combination of same with chimeric antigen receptor cell, and use thereofINNOVENT CELLS PHARMACEUTICALS SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 1655US2023272082A1Anti-vista antibodies and uses thereofSENSEI BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Nadthakarn Boland files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →